Watch for Dosing Confusion with Ceftolozane/Tazobactam

March 2015

Please see the FDA safety warning (May 2015) concerning dose confusion/medication errors associated with Zerbaxa

Reps will be promoting a new IV anti-infective, ceftolozane/tazobactam (Zerbaxa).

Ceftolozane/tazobactam is approved for complicated UTIs (cUTIs) and intra-abdominal infections (cIAIs) in adults...and higher doses are still being studied for ventilator-associated pneumonia.

Think of it as primarily covering gram-negative bacteria...including Pseudomonas and ESBL-producing Enterobacteriaceae.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Readmissions Integrate Pharmacy Staff Into the Medication History Process
Vaccines Help Debunk The Myth That Thimerosal Causes Autism
New Drugs Use Actual Body Weight When Calculating Renal Function For Edoxaban
New Drugs Switch Unit-Per-Unit From Afrezza to Your Formulary Rapid-Acting Insulin
New Drugs Watch for Dosing Confusion with Ceftolozane/Tazobactam
Med Safety Use Safety Huddles to Report IV Room Errors or Near Misses
Kidney Stones Use NSAIDs Instead of Opioids for Kidney Stone Pain
Women's Health Educate About A Small Risk of Neural Tube Defects With Opioids
Practice Re-Titrate Lisdexamfetamine At Discharge If It's Stopped For Several Days
Diabetes Don't Worry About Stopping Metformin For Contrast Procedures in Healthy Patients
Infectious Diseases Consider Steroids for CAP Patients on the Floor

Watch for Dosing Confusion with Ceftolozane/Tazobactam

Get unlimited access through an Enterprise license

Table of Contents